在线办公
期刊论坛
主 管
中国人民解放军总医院
主 办
中国人民解放军总医院老年心血管病研究所
中国科技出版传媒股份有限公司
编 辑
中华老年多器官疾病杂志编辑委员会
100853, 北京市复兴路28号
电话:010-66936756
传真:010-66936756
E-mail: zhlndqg@mode301.cn
创刊人 王士雯
总编辑 范利
副总编辑 陈韵岱
执行主编 叶大训
编辑部主任 王雪萍
ISSN 1671-5403
CN 11-4786
创刊时间 2002年
出版周期 月刊
邮发代号 82-408
友情链接
陈振道,苏艺,陈浩,祝斌,王亚瑞.替普瑞酮联合法莫替丁防治抗血小板药物所致胃肠道损伤的效果观察[J].中华老年多器官疾病杂志,2019,18(8):565~568
替普瑞酮联合法莫替丁防治抗血小板药物所致胃肠道损伤的效果观察
Therapeutic effect of teprenone combined with famotidine on gastrointestinal injury caused by antiplatelet drugs
投稿时间:2019-04-04  
DOI:10.11915/j.issn.1671-5403.2019.08.122
中文关键词:  胃肠道;抗血小板药物;替普瑞酮
英文关键词:gastrointestinal tract; antiplatelet drug; teprenone
基金项目:国家自然科学基金(81300279);中国博士后科学基金(2012M521579);广东省自然科学基金(S2013040013549)
作者单位E-mail
陈振道 广东省化州市人民医院消化内科,化州 525100 czd2043@sina.com 
苏艺 广东省化州市人民医院消化内科,化州 525100  
陈浩 广东省人民医院消化内科,广州 510000  
祝斌 广东省化州市人民医院消化内科,化州 525100  
王亚瑞 广东省化州市人民医院消化内科,化州 525100  
摘要点击次数: 85
全文下载次数: 110
中文摘要:
      目的 观察替普瑞酮联合法莫替丁防治抗血小板药物所致胃肠损伤的疗效。方法 选取2016年8月至2018年11月化州市人民医院收治的胃肠道损伤患者84例。依据治疗方法分为3组:质子泵抑制剂(PPI)组、H2受体拮抗剂(H2RA)组和联合治疗组,每组28例。所有患者均继续进行抗血小板治疗。PPI组服用泮托拉唑;H2RA组服用法莫替丁;联合治疗组在H2RA组基础上加服替普瑞酮。共治疗6个月。对比3组患者治疗前后各指标变化情况。采用SPSS 24.0软件进行数据处理。结果 治疗后,联合治疗组患者的前列腺素E2(PGE2)显著高于PPI组和H2RA组[(83.46±16.83) vs(46.61±14.53) vs(55.67±18.49)ng/L],血栓素B2(TXB2)显著低于PPI组和H2RA组[(139.96±48.69) vs(297.38±44.09) vs(173.82±51.25)pg/L],基础胃酸分泌量高于PPI组、低于H2RA组[(3.86±0.67) vs(2.29±0.56) vs(4.97±0.89)mmol/h],差异具有统计学意义(P<0.05)。治疗后联合治疗组患者胃[(0.76±0.37) vs(3.38±2.11) vs(3.04±1.93)分]和十二指肠[(0.81±0.32) vs(3.19±1.52) vs(2.91±1.49)分]黏膜的改良Lanza量表评分显著低于PPI组与H2RA组(P<0.05)。联合治疗组患者不良反应发生率显著低于PPI组和H2RA组(17.9% vs 53.6% vs 28.6%,P<0.05)。结论 替普瑞酮联合法莫替丁防治抗血小板药物所致胃肠损伤的疗效显著且不良反应少,值得临床推广应用。
英文摘要:
      Objective To observe the efficacy of teprenone combined with famotidine in the prevention and treatment of gastro-intestinal injury caused by antiplatelet drugs. Methods A total of 84 patients with gastrointestinal injuries caused by antiplatelet drugs admitted in Huazhou People′s Hospital from August 2016 to November 2018 were enrolled in this study. They were divided into 3 groups (n=28), that is, proton pump inhibitor group (PPI, pantoprazole), H2 receptor antagonist group (H2RA, famotidine), and combined treatment group (teprenone and famotidine). All patients continued to receive antiplatelet therapy. The related indicators were observed before and in 6 months after treatment, and the results were compared among the 3 groups. SPSS statistics 24.0 was used to perform the statistical analysis. Results After treatment, the combined treatment group had significantly higher prostaglandin E2 level [PGE2, (83.46±16.83) vs (46.61±14.53) vs (55.67±18.49)ng/L], but obviously lower thromboxane B2 [TXB2,(139.96±48.69) vs (297.38±44.09) vs (173.82±51.25)pg/L] when compared with the PPI group and the H2RA group. But the gastric acid secretion in the combined treatment group was higher than the PPI group and lower than the H2RA group [(3.86±0.67) vs(2.29±0.56) vs(4.97±0.89)mmol/h, P<0.05]. What′s more, the modified Lanza scale scores of the gastric and duodenal mucosa in the combined treatment group were significantly lower than those in the PPI group and the H2RA group [(0.76±0.37) vs (3.38±2.11) vs (3.04±1.93), (0.81±0.32) vs (3.19±1.52) vs (2.91±1.49), P<0.05]. The incidences of adverse reactions were also significantly lower in the combined treatment group than the other 2 groups (17.9% vs 53.6% vs 28.6%, P<0.05). Conclusion The combination of teprenone and famotidine exerts significant efficacy and has few adverse reactions in the prevention and treatment of gastrointestinal injuries caused by antiplatelet drugs, which is worthy of clinical application.
查看全文    下载PDF阅读器
关闭